Soliris Treats Rare Case of aHUS Due to Scleroderma Renal Crisis

Soliris (eculizumab) safely and effectively treated a 46-year-old man with atypical hemolytic uremic syndrome (aHUS) secondary to a scleroderma renal crisis — a life-threatening complication of an autoimmune disorder that can lead to kidney failure. His case was described in the study, “Atypical hemolytic-uremic syndrome due to a scleroderma renal crisis…

Fewer Children, More Blacks Hospitalized for HUS in US, 2007-18

The demographics of people hospitalized for hemolytic uremic syndrome (HUS) in the U.S. have shifted over the last decade, with a lower proportion of young children and a higher number of Black patients, a new study reports. “Further surveillance is required to determine if these trends continue,” the researchers wrote.

Soliris, a Treatment for aHUS, Is Now Available in China

Soliris (eculizumab), an approved treatment for atypical hemolytic uremic syndrome (aHUS), is now available to patients in China, AstraZeneca announced. “This milestone reflects our ambition to bring transformative, rare disease medicines to the significant number of patients and families living with rare diseases in China who currently have…